Gilberto L. Lopes
Expertise in
25
conditions

Dr. Gilberto L. Lopes

Oncology
1475 Northwest 12th Avenue, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Expertise in
25
conditions
1475 Northwest 12th Avenue, 
Miami, FL 

Overview

Dr. Gilberto Lopes is a medical oncologist and researcher who focuses on new anticancer drug development and global oncology. He has published more than 270 scientific papers and has led hundreds of clinical trials. Dr. Lopes was the main investigator of Keynote 42, a clinical trial that demonstrated the efficacy of the immunotherapy drug pembrolizumab in people living with lung cancer. This groundbreaking study led to one of the FDA approvals of pembrolizumab. Additionally, Dr. Lopes has contributed significantly to the development of several chemotherapies and targeted medications that address specific molecular changes in tumors. He also does research in cancer control, policy and health economics and is active in improving access to cancer medications in underserved settings.

Dr. Lopes is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

He is actively involved in clinical research, co-authoring 164 peer reviewed articles and participating in 4 clinical trials. Dr. Lopes is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Fellowships

Jackson Memorial Hospital Division of Hematology/Oncology, Hematology/Oncology - 2006

Hospital Affiliations

Jackson Health System

Languages Spoken

English
Portuguese
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Guardian Life Insurance Company
  • MEDICARE PDP
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

1475 Northwest 12th Avenue, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Enrolling_by_invitation
Publish Date: August 11, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Enrollment Status: Terminated
Publish Date: June 17, 2026
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Study Phase: Phase 3
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: September 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

164 Total Publications

Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US.
Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US.
Journal: JAMA oncology
Published: August 20, 2026
Similar Doctors
Expertise in
58
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Expertise in
58
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Referral may be required
1295 Northwest 14th Street, 
Miami, FL 
 (0.1 miles away)
305-243-6946
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Komotar is an Oncologist and a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Komotar is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Meningioma, Glioblastoma, Awake Craniotomy, and Posterior Fossa Decompression. Dr. Komotar is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (0.1 miles away)
305-243-1287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Breelyn Wilky is an Oncologist practicing medicine in Miami, Florida. Dr. Wilky is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Desmoid Tumor, and Gastrointestinal Stromal Tumor. Dr. Wilky is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (10.7 miles away)
786-345-7208
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Ahluwalia is an Oncologist practicing medicine in Miami, Florida. Dr. Ahluwalia is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

Frequently Asked Questions about Dr. Gilberto L. Lopes

How do I make an appointment with Dr. Gilberto L. Lopes?

You can book an appointment with Dr. Gilberto L. Lopes by calling their office at 305-243-5302. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gilberto L. Lopes a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gilberto L. Lopes is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gilberto L. Lopes specialize in?

While Dr. Gilberto L. Lopes is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Gilberto L. Lopes participate in research or clinical trials?

Yes. Dr. Gilberto L. Lopes has published 164 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Gilberto L. Lopes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gilberto L. Lopes accept my insurance?

Dr. Gilberto L. Lopes accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-243-5302 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lopes's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 64 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile